Shares of Poniard Pharmaceuticals (PARD) -8.8% after the firm said it's replacing its CEO and...

|About: Poniard Pharmaceuticals... (PARD)|By:, SA News Editor

Shares of Poniard Pharmaceuticals (PARD) -8.8% after the firm said it's replacing its CEO and cutting its work force by 57%. Moves come after disappointing results last week from a Phase II trial of its cancer drug picoplatin. Shares are down 76% over the past three months.